Business Standard

Wednesday, January 01, 2025 | 03:48 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Aurobindo Pharma faces class action suit in US for concealing facts

Aurobindo Pharma allegedly concealed facts about cancer-causing agent NDMA in type-2 diabetes drug metformin

medicine
Premium

Representative Image

BS Web TeamAgencies
A class action suit has been filed against Aurobindo Pharma and Emcure Pharmaceuticals in a Florida court for allegedly concealing information about cancer-causing agent, N- nitrosodimethylamine (NDMA) presence in metformin medicine.

MSP Recovery Claims filed the petition on April 3 in U.S. District Court for the Southern District of Florida on behalf of similarly-situated healthcare insurers to recover payments unlawfully induced by the drug makers- Aurobindo Pharma, Aurolife Pharma, LLC and Heritage Pharmaceuticals LLC.

Metformin is the most prescribed oral pharmaceutical drug for patients with type-2 diabetes. The petition was based on tests done by Valisure, an online pharmacy.

Valisures

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in